Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Frank Mottola Sells 1,110 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Frank Mottola sold 1,110 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $28.13, for a total value of $31,224.30. Following the sale, the senior vice president now owns 5,681 shares of the company’s stock, valued at $159,806.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Supernus Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:SUPN opened at $27.43 on Friday. The business has a fifty day moving average of $26.51 and a two-hundred day moving average of $30.32. The stock has a market cap of $1.50 billion, a P/E ratio of 66.90 and a beta of 1.08. Supernus Pharmaceuticals, Inc. has a 52-week low of $21.99 and a 52-week high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.42). Supernus Pharmaceuticals had a net margin of 4.20% and a return on equity of 2.82%. The business had revenue of $153.88 million during the quarter, compared to analyst estimates of $143.39 million. During the same period last year, the company earned $0.03 EPS. The business’s revenue for the quarter was down 13.2% on a year-over-year basis. On average, equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.59 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Piper Sandler upped their target price on Supernus Pharmaceuticals from $42.00 to $43.00 and gave the company an “overweight” rating in a report on Thursday, November 9th. StockNews.com cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently bought and sold shares of SUPN. Natixis Advisors L.P. lifted its stake in Supernus Pharmaceuticals by 15.3% during the 1st quarter. Natixis Advisors L.P. now owns 31,126 shares of the specialty pharmaceutical company’s stock worth $1,006,000 after acquiring an additional 4,129 shares in the last quarter. Bank of Montreal Can lifted its stake in Supernus Pharmaceuticals by 10.3% during the 1st quarter. Bank of Montreal Can now owns 15,996 shares of the specialty pharmaceutical company’s stock worth $519,000 after acquiring an additional 1,488 shares in the last quarter. MetLife Investment Management LLC raised its position in Supernus Pharmaceuticals by 54.9% in the 1st quarter. MetLife Investment Management LLC now owns 27,869 shares of the specialty pharmaceutical company’s stock valued at $901,000 after purchasing an additional 9,872 shares in the last quarter. Rhumbline Advisers raised its position in Supernus Pharmaceuticals by 2.4% in the 1st quarter. Rhumbline Advisers now owns 148,330 shares of the specialty pharmaceutical company’s stock valued at $4,794,000 after purchasing an additional 3,477 shares in the last quarter. Finally, Sei Investments Co. raised its position in Supernus Pharmaceuticals by 2.4% in the 1st quarter. Sei Investments Co. now owns 223,149 shares of the specialty pharmaceutical company’s stock valued at $7,217,000 after purchasing an additional 5,196 shares in the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.